This NYT investigation shows how RFK Jr’s lawyer and long-time colleague Aaron Siri benefits financially from his influence over RFK and HHS, resulting in vaccine policies and other decisions that harm U.S. patients. NCHR president Diana Zuckerman’s experience is included as an example.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
New Blood Tests for Early Cancer Detection Get Some Love From House Members
MedPage Today, September 18, 2025: This news article describes Energy & Commerce Health Committee hearing on bills that would require Medicare cover Breakthrough devices and controversial Multi-cancer Screening tests. NCHR president Dr. Diana Zuckerman testified, describing the cancer tests as “not ready for prime time” and explaining that the latest research shows they are very inaccurate, with some having a false positive rate over 90%
Read More »FDA Leaders Moving to Abandon Advisory Committee Reviews of Specific New Drugs
STAT News, September 12, 2025: FDA seeks to abandon Advisory Committees for specific drugs and use them for bigger issues says CDER head George Tidmarsh. We point out that Expert Panels are also replacing Advisory Committees with one-sided reviews.
Read More »The Business of Pet Adoption
September 5, 2025, The Times-Journal (Alabama): Pets play a leading role in many people’s lives. Researchers tell us that companion animals (pets) improve human health and well-being. For example, pets can help lower blood pressure, improve heart health, have fewer sick days, and get more exercise.
Read More »FDA Expert Panels Lack Balance in Pursuit of ‘Gold Standard Science’
BioSpace, September 8, 2025: NCHR’s Dr. Diana Zuckerman tells BioSpace that the new FDA expert panels, such as those on SSRI’s during pregnancy and hormone therapy for menopause are more biased than FDA Advisory Committees and lack nuance about complicated data. They send a message to industry about what changes FDA wants to make.
Read More »